https://charts.traderzeitung.de/phases/US36322Q2066 string(1422) "{"isin":"US36322Q2066","name":"Damora Therapeutics Inc","stock_id_xnas":65845133,"stock_id_xnys":null,"generated_at":"2026-09-24 01:32:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":22.88,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":22.41,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":-2.0542},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":20.47,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-8.6568},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":20.81,"close_at":"2026-09-23 22:03:00","complete":false,"perf_pct":1.661}]}]}"

Damora Therapeutics Aktie News & Nachrichten

[WKN: A40M33 | Symbol: DMRA]

Realtimekurs

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3, lysyl oxidase-like 2, and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Damora Therapeutics gefunden werden.

Damora Therapeutics Nachrichtenticker öffnen

MT Newswires 05.08.2026 16:43 Uhr

Damora Therapeutics Aktie News & Nachrichten

Artikel aus der Redaktion der Trader-Zeitung

Damora Therapeutics beginnt Studie mit DMR-001 bei ET, Myelofibrosis

Wedbush passt das Kursziel für Damora Therapeutics von $35 auf $40 an und beibehält das Outperform-Rating

Jefferies nimmt Damora Therapeutics mit Buy-Rating und einem Kursziel von 50 USD neu auf

Damora Therapeutics schließt Redomestizierung auf die Cayman Islands ab

HC Wainwright nimmt die Coverage von Damora Therapeutics mit 'Kaufen'-Rating und einem Kursziel von $45 auf

TD Cowen nimmt die Coverage von Damora Therapeutics mit 'Kaufen' auf

Wedbush nimmt die Coverage für Damora Therapeutics mit der Bewertung 'Outperform' und einem Kursziel von $35 auf